<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">19185011</PMID>
<DateCompleted>
<Year>2009</Year>
<Month>07</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>24</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2009</Year>
<Month>Apr</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>How cautious should we be when assessing apathy with the Unified Parkinson's Disease Rating Scale?</ArticleTitle>
<Pagination>
<MedlinePgn>684-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22437</ELocationID>
<Abstract>
<AbstractText>Current practice often assesses apathy with a single item from the Unified Parkinson's Disease Rating Scale (UPDRS, item 4). Yet, the relationship between the UPDRS item 4 and the validated Apathy Scale (AS) is unknown. The purpose of this study was to evaluate the operating characteristics of UPDRS item 4 in relation to the AS. Three hundred and one patients with PD were administered the AS and the UPDRS. We compared the UPDRS item 4 to the standard AS classification of &gt; or =14 as apathetic. A receiver operating characteristics (ROC) curve was obtained, and sensitivity, specificity, positive, and negative predictive power were calculated. The ROC curve showed area under the curve as 0.75. A cut-off of 1 had good sensitivity (81%) but poor specificity (53%; high false positive rate). A cut-off point of 2 had acceptable specificity (87%) but poor sensitivity (52%, high false negative rate). Continuing to increasing the cut-off point (e.g., 3, 4) continues to increase specificity at the expense of dramatically reducing sensitivity. These findings suggest the use of caution when screening for apathy with item 4 due to its poor sensitivity in relation to the AS.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kirsch-Darrow</LastName>
<ForeName>Lindsey</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Clinical and Health Psychology, College of Public Health and Health Professions, University of Florida, Gainesville, Florida 32610-0165, USA. lkirsch@phhp.ufl.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zahodne</LastName>
<ForeName>Laura B</ForeName>
<Initials>LB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hass</LastName>
<ForeName>Chris</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mikos</LastName>
<ForeName>Ania</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Okun</LastName>
<ForeName>Michael S</ForeName>
<Initials>MS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fernandez</LastName>
<ForeName>Hubert H</ForeName>
<Initials>HH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bowers</LastName>
<ForeName>Dawn</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>T32 AG020499-09</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K23 NS044997</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>F31 NS059142</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-NS05063</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>F31-NS059142</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K23-NS044997</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 NS050633</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 AG020499</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D023362">Evaluation Studies</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019964">Mood Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012372">ROC Curve</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012680">Sensitivity and Specificity</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2009</Year>
<Month>2</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2009</Year>
<Month>2</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2009</Year>
<Month>7</Month>
<Day>29</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">19185011</ArticleId>
<ArticleId IdType="doi">10.1002/mds.22437</ArticleId>
<ArticleId IdType="pmc">PMC3045863</ArticleId>
<ArticleId IdType="mid">NIHMS267987</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Mov Disord. 2002 Mar;17(2):366-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11921125</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):636-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12438462</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Affect Disord. 2004 Feb;78(2):131-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14706723</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1564476</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):243-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1821241</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):134-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1627973</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Chem. 1993 Apr;39(4):561-77</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8472349</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neurol Neurosurg Psychiatry. 1999 Oct;67(4):492-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10486397</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neurol Neurosurg Psychiatry. 2006 May;77(5):579-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16614016</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neurology. 2006 Jul 11;67(1):33-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16832074</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mov Disord. 2007 Nov 15;22(15):2156-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17721877</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Parkinsonism Relat Disord. 2008;14(3):183-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17889589</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neurol Neurosurg Psychiatry. 2008 Oct;79(10):1088-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18187477</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>